Deguchi K, Yokota N, Koguchi M, Suzuki Y, Fukayama S, Ishihara R, Oda S, Tanaka S, Nakane Y, Fukumoto T
Section of Studies, Tokyo Clinical Research Center.
Jpn J Antibiot. 1994 Dec;47(12):1753-61.
Antibacterial activities of cefetamet (CEMT) against clinically isolated strains from patients with community acquired respiratory tract infections were compared to those of other oral beta-lactam antibiotics in the period from January to March 1994. The following results were obtained. 1. CEMT showed strong antibacterial activities against three major pathogens causing community acquired respiratory tract infections, Streptococcus pyogenes, Streptococcus pneumoniae, and Haemophilus influenzae. However, antibacterial activities of CEMT against benzylpenicillin (PCG)-insensitive S. pneumoniae (PISP) and PCG-resistant S. pneumoniae (PRSP) were slightly weaker than of those of some the reference antibiotics. 2. No MIC value changes of CEMT were observed from year to year against Moraxella subgenus Branhamella catarrhalis and Klebsiella pneumoniae.
1994年1月至3月期间，比较了头孢他美酯（CEMT）对社区获得性呼吸道感染患者临床分离菌株的抗菌活性与其他口服β-内酰胺类抗生素的抗菌活性。获得了以下结果。1. CEMT对引起社区获得性呼吸道感染的三种主要病原体化脓性链球菌、肺炎链球菌和流感嗜血杆菌显示出较强的抗菌活性。然而，CEMT对苄青霉素（PCG）不敏感的肺炎链球菌（PISP）和PCG耐药的肺炎链球菌（PRSP）的抗菌活性略弱于某些参考抗生素。2. 每年未观察到CEMT对卡他莫拉菌莫拉克斯氏菌属和肺炎克雷伯菌的MIC值变化。
